AlzGene

AlzGene - Gene overview of all published AD-association studies for LRP1

Gene:

LRP1 (APR; LRP; A2MR; CD91; APOER)

View on MSGene View on PDGene

Protein:

low density lipoprotein-related protein 1 (alpha-2-macroglobulin receptor)

Chromosome:

12 (View: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 X Y MT)

Status:

Updated 18 April 2011

1. Case-Control Studies (by ethnic group)
				AD Cases				Normal Controls
Study	Population	Source	# Polys	# Subjects (% women)	DX	Onset Age (range)	Age (range)	# Subjects (% women)	Age (range)	Result	Comment
Caucasian
Bahia, 2008	Brazil	CL	1 (detail)	120 (68%)	C	71.1 + 9.5 (-)	75.2 + 9.2 (-)	120 (63%)	72.5 + 8.6 (-)	Negative
Beffert, 1999	Canada	CL	1 (detail)	225 (48%)	N	70.9 + 10.1 (59-96)	77.6 + 9 (-)	187 (41%)	70.5 + 10.6 (54-94)	Negative
Blomqvist, 2005	Overlaps with Emahazion, 2001	CL	1 (detail)	121 (58%)	C	-	57.8 + 6.3 (-)	165 (37%)	58.3 + 9.9 (-)	n.a.
Blomqvist, 2005	Overlaps with Prince, 2001	CL	1 (detail)	819 (63%)	M	-	76.2 + 7.1 (-)	240 (59%)	73.2 + 9.3 (-)	n.a.
Bullido, 2000	Spain	CL	2 (detail)	154 (60%)	C	70.4 + 6.3 (-)	-	217 (62%)	72 + 7.6 (-)	Trend
Corder, 2008	Overlaps with Blomqvist, 2005	CL	1 (detail)	938 (-)	U	-	-	397 (-)	-	n.a.
Depboylu, 2006	Germany	CL	1 (detail)	271 (37%)	C	-	70.7 + 9.6 (50-95)	280 (31%)	66.9 + 10.6 (50-93)	Negative
Edwards, 2009	USA	CL	10 (detail)	296 (-)	M	71.7 + 7.8 (-)	79 + 6.6 (-)	566 (-)	73.6 + 6.3 (-)	Negative
Emahazion, 2001	Scotland	CL	1 (detail)	121 (-)	C	-	-	152 (-)	-	Negative
Helbecque, 2001	Europe (mixed)	CL	1 (detail)	243 (65%)	M	-	74 + 10 (-)	250 (68%)	79 + 8 (-)	Negative
Helbecque, 2001	France	CL	1 (detail)	56 (80%)	M	-	85 + 6 (-)	180 (51%)	79 + 6 (-)	Negative
Hollenbach, 1998	USA	CL	1 (detail)	150 (-)	M	68.9 + 9 (45-103)	-	93 (-)	71.9 + 11.7 (49-102)	Positive
Kamboh, 1998	Overlaps with Luedecking, 2003	CL	2 (detail)	432 (62%)	M	68.6 + 8.3 (-)	75.4 + 8.5 (-)	106 (59%)	67.8 + 10.7 (-)	Negative
Kang, 1997	USA	CL	1 (detail)	157 (53%)	M	73.2 + 4.5 (88-87)	-	102 (53%)	76.2 + 5.9 (66-95)	Positive
Koelsch, 2003	Germany	CL	1 (detail)	212 (71%)	C	-	73.1 + 9.4 (-)	337 (61%)	73.2 + 7.8 (-)	Positive
Lambert, 1998	France	CL	1 (detail)	558 (68%)	C	68.6 + 8.2 (-)	71.8 + 8.1 (-)	596 (63%)	72.7 + 8.3 (-)	Positive
Lambert, 1999	France	CL	1 (detail)	600 (62%)	U	68.7 + 8.1 (-)	72 + 8 (-)	646 (63%)	72.5 + 8.2 (-)	Positive
Lendon, 1997	Unknown	CL	1 (detail)	183 (50%)	C	70.5 + 10.8 (60-92)	76.7 + 10.7 (-)	118 (54%)	78.6 + 10.7 (-)	Positive
Li, 2008	Canada	CL	1 (detail)	753 (58%)	C	71.9 + 8.5 (-)	77.8 + 8.6 (-)	736 (64%)	73.4 + 7.9 (-)	Negative
Luedecking-Zimmer, 2003	USA	CL	3 (detail)	564 (68%)	M	72.6 + 8.3 (-)	77.3 + 6.4 (-)	523 (66%)	76.8 + 6.3 (-)	Negative
McIlroy, 2001	Ireland	CL	2 (detail)	219 (67%)	C	75.1 (-)	77.5 + 6 (-)	237 (70%)	77.2 + 6.1 (-)	Negative
Myllykangas, 2000	Finland	PO	1 (detail)	121 (87%)	N	-	92.2 + 3.1 (-)	75 (83%)	92.3 + 3.8 (-)	Negative
Panza, 2004	Italy	CL	1 (detail)	166 (63%)	C	67.6 + 10.8 (-)	69.4 + 10.3 (-)	225 (68%)	71.3 + 10.4 (-)	Negative
Papassotiropoulos, 2005	I (Greece)	CL	1 (detail)	134 (-)	C	-	-	45 (-)	-	Negative
Papassotiropoulos, 2005	II (Germany, Switzerland)	CL	1 (detail)	150 (-)	C	-	-	216 (-)	-	Negative
Prince, 2001	Sweden	CL	1 (detail)	204 (61%)	M	-	-	186 (58%)	-	Negative
Pritchard, 2005	UK	CL	1 (detail)	466 (-)	M	-	-	477 (-)	-	Negative
Rodriguez, 2005	Overlaps with Sanchez-Guerra, 2001	CL	1 (detail)	274 (68%)	C	71.6 + 8.6 (48-94)	75.4 + 8.7 (50-97)	283 (71%)	80.5 + 7.9 (63-100)	n.a.
Sanchez-Guerra, 2001	Spain	CL	1 (detail)	305 (68%)	C	71.8 + 8.7 (40-95)	75.5 + 8.8 (50-98)	304 (72%)	80.4 + 7.8 (63-100)	Negative
Schahab, 2006	Overlaps with Koelsch, 2003	CL	1 (detail)	-	-	-	-	-	-	n.a.
Scott, 1998	USA	CL	1 (detail)	615 (61%)	U	69.3 + 8.4 (-)	74.1 + 8.1 (-)	240 (56%)	70.7 + 8.5 (-)	Negative
Vargas, 2010	Spain	CL	1 (detail)	1158 (66%)	C	73.7 + 7.9 (-)	-	1025 (68%)	74.7 + 11.8 (-)	Negative
Vazquez-Higuera, 2009	Overlaps with Sanchez-Guerra, 2001	CL	1 (detail)	246 (65%)	C	72.9 + 7.1 (60-93)	76.6 + 7.3 (62-97)	237 (69%)	81.2 + 7.7 (63-100)	n.a.
Verpillat, 2001	France	CL	2 (detail)	274 (56%)	C	65.5 + 9.8 (41-90)	-	290 (57%)	67.4 + 10 (43-93)	Trend
Wavrant-DeVrieze, 1997	France		1 (detail)	144 (69%)	C	-	77.3 + 8.9 (-)	153 (69%)	79.3 + 9.3 (-)	Positive
Wavrant-DeVrieze, 1999	France	CL	1 (detail)	665 (64%)	U	69.2 + 8.6 (-)	73 + 8.7 (-)	671 (63%)	73.1 + 8.5 (-)	Positive
Wehr, 2006	Poland	CL	2 (detail)	100 (66%)	C	-	71.8 + 7.9 (52-91)	144 (53%)	70.5 + 8.8 (47-93)	Negative
Woodward, 1998	UK		1 (detail)	133 (-)	M	-	82 + 6.2 (67-98)	70 (-)	81.8 + 6.9 (68-104)	Negative
Asian
Baum, 1998	China	CL	1 (detail)	143 (-)	M	-	78.5 + 7.4 (-)	129 (-)	78.2 + 6.6 (-)	Positive
Bi, 2001	China	CL	1 (detail)	38 (45%)	C	-	70.2 + 6.7 (-)	40 (40%)	69.2 + 8.4 (-)	Positive
Bian, 2005	China	CL	4 (detail)	216 (-)	C	74.7 (-)	-	200 (-)	72 (-)	Positive
Hatanaka, 2000	Japan	CL	2 (detail)	100 (68%)	U	76.6 + 7.4 (65-98)	-	246 (-)	79.7 + 8 (62-101)	Trend
Hu, 2000	Taiwan	CL	1 (detail)	82 (-)	C	-	78.2 (62-96)	110 (-)	79.2 (67-87)	Negative
Zhou, 2008	China	CL	1 (detail)	496 (54%)	C	72.2 + 10.3 (-)	79.2 + 10.6 (-)	478 (45%)	75.3 + 9 (-)	Positive
Hispanic
Forero, 2005	Colombia	CL	1 (detail)	106 (71%)	C	68.8 + 8.7 (-)	73.3 + 8.8 (-)	97 (-)	72.2 + 8.7 (-)	Negative
Other/Mixed
Causevic, 2003	USA	CL	1 (detail)	41 (-)	M	-	-	20 (-)	-	Negative
Clatworthy, 1997	USA	CL	1 (detail)	130 (-)	M	-	78.2 + 8.9 (-)	64 (-)	81.7 + 12.3 (-)	Negative
Fallin, 1997	USA	CO	1 (detail)	62 (53%)	C	74.5 + 8.2 (-)	-	282 (63%)	72.6 + 7 (-)	Positive
Perry, 2001	USA	CL	1 (detail)	111 (69%)	M	70.8 + 7.8 (-)	71.3 + 7.7 (-)	78 (76%)	75.2 + 7.6 (-)	Negative

Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.

2. Family-Based Studies (by ethnic group)
				Affecteds				Unaffecteds
Study	Population	# Polys	# Families	# Subjects (% women)	DX	Onset Age (range)	Age (range)	# Subjects (% women)	Age (range)	Result	Comment
Other/Mixed
Bertram, 2000	USA	0	220	460 (-)	M	-	-	367 (-)	-	Negative

Contact us if you are an author of an association study regarding this gene and do not find your study in this table or find errors in the representation of your study details.

Source:  Source of case population -> “CL” (clinic-based), “PO” (population-based), or “CO” (community-based).
# Polys:  Number of polymorphisms tested per gene and per sample.
Onset Age and Age:  Mean or median age at onset or examination, respectively.
DX:  Criteria used to determine AD diagnosis -> "C" (clinical AD diagnosis), "N" (neuropathological AD diagnosis), "M" (mixed, i.e. AD sample contains both clinical and neuropathological cases), "U" (unknown).
Result:  Overall conclusion reached by authors of the original publication (“positive” usually indicates significant (P<0.05) association in at least one of the performed analyses, and “negative” indicates no evidence for significant association, while “trend” indicates results in between); results obtained in duplicate or largely overlapping samples are listed as "n.a.".
(-) :  Either no data provided or in case of overlap, data included in original study.

AlzGene Recent Updates

AlzGene Top Results